Establishment and characterization of new pre-B cell leukemia cell line NALM-26.
A new pre-B cell leukemia cell line, NALM-26, was established from the peripheral blood of a 24-year-old male patient with acute pre-B cell leukemia. NALM-26 is unique in its expression of T cell-associated CD5 and myeloid cell-associated CD13 antigens. Interleukin-7 (IL-7) receptor (CDw127) was detected by flow cytometric analysis. After PMA treatment, NALM-26 was induced to express CD20, CD25 and CD28, and to increase its expression of both CD5 and CD13. The expression of CDw127 was down-modulated.
Matsuo
Y
Y
Fujisaki Cell Center, Hayashibara Biochemical Labs, Inc., Okayama.
Adachi
T
T
Tsubota
T
T
D000328:Adult; D015703:Antigens, CD / Q000032:analysis; D006801:Humans; D008297:Male; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology / Q000473:pathology*; D018123:Receptors, Interleukin / Q000032:analysis; D020395:Receptors, Interleukin-7; D014407:Tumor Cells, Cultured
D015703:Antigens, CD; D018123:Receptors, Interleukin; D020395:Receptors, Interleukin-7